| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/11/1999 | CA2290750A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | CA2290747A1 Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | CA2290746A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/10/1999 | EP0896055A2 Apoptosis inducing protein and gene encoding the same |
| 02/10/1999 | EP0895989A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity |
| 02/10/1999 | EP0895988A1 Arylsulfonylamino hydroxamic acid derivatives |
| 02/10/1999 | EP0895783A2 Pharmaceutical composition comprising ifosfamide and carnitine |
| 02/10/1999 | EP0895475A1 Vitronectin receptor antagonists |
| 02/10/1999 | EP0693120B1 Tumoricide t lymphocytes |
| 02/10/1999 | CN1207811A Method of diagnosing and treating epithelioma |
| 02/10/1999 | CN1207775A Conditionally replicating viral vectors and their use |
| 02/10/1999 | CN1207771A Methods and compositions for diagnosis and treatment of cancer |
| 02/10/1999 | CN1207769A Tissue-specific and target RNA-specific ribozymes |
| 02/10/1999 | CN1207743A Inhibitors of interleukin-1 'beta' converting enzyme |
| 02/10/1999 | CN1207741A Synthetic metal-substituted bacteriochlorophyll derivs. and use thereof |
| 02/10/1999 | CN1207740A Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides |
| 02/10/1999 | CN1207734A Metalloproteinase inhibitors, pharmaceutical compositions contg. them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
| 02/10/1999 | CN1207686A FC 'epsilon'-PE chimeric protein for targeted treatment of allergy responses, method for its production and pharmaceutical compositions contg. same |
| 02/10/1999 | CN1207321A Oral liquid for treating tumor |
| 02/10/1999 | CN1207309A Process for preparation of Rhus verniciflus extract and anti-cancer composition containing same |
| 02/10/1999 | CN1042032C Anthracycline disaccharides, process for their preparation, and pharmaceutical compositions contg. them |
| 02/10/1999 | CN1042026C 25 carboxylic deriv. of vitamin D series, its preparing method, middle products in production of same and medicine contg. same and pharmaceutical use of same in treatment |
| 02/09/1999 | US5869734 Chemical intermediate to the production of deoxyspergualin and salts |
| 02/09/1999 | US5869680 Reacting a oxazolidine derivative with protected hydroxy-taxol; decyclization and amination |
| 02/09/1999 | US5869663 Intermediates for neurokinin receptor antagonists |
| 02/09/1999 | US5869636 Recombinant cell line expressing polypetide for anticarcinogenic and antitumor agents and vaccines |
| 02/09/1999 | US5869610 Isolated polypeptide identified as a cytokine receptor containing extracellular, transmembrane and intracellular domains; prenatal testing and cancer diagnosis |
| 02/09/1999 | US5869535 Method and composition for selectively inhibiting melanoma |
| 02/09/1999 | US5869531 No undesireable salidiuretic properties; treating ischemia induced disorders |
| 02/09/1999 | US5869514 Terpenoidic derivatives useful as antitumor agents |
| 02/09/1999 | US5869511 Isoxazoline compounds as inhibitors of TNF release |
| 02/09/1999 | US5869507 Increased bioavailability; anti-tumor activity with selective inhibition of ras-transformed cell lines over wild-type cells |
| 02/09/1999 | US5869485 Treatment of diseases which respond to inhibition of the activity of the protein tyrosine kinase |
| 02/09/1999 | US5869464 Having low toxicity, sustaining low concentration in blood for extended period |
| 02/09/1999 | US5869293 DNA encoding human interferon IFN -α001 |
| 02/09/1999 | US5869282 Nucleotide and protein sequences of the serrate gene and methods based thereon |
| 02/09/1999 | US5869271 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 02/09/1999 | US5869248 Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
| 02/09/1999 | US5869246 Triplex Oligonucleotides targeted to p120 |
| 02/09/1999 | US5869053 5T4 antigen from human trophoblasts |
| 02/09/1999 | US5869040 Administering interfering mutant proto-oncogene or oncoprotein to target cell |
| 02/09/1999 | US5869037 Adenoviral-mediated gene transfer to adipocytes |
| 02/09/1999 | US5869035 Through transfer techniques, cancer cells are engineered to express an epitope which is targeted by natural antibodies causing complement destruction of transformed tumor cells associated with hyperacute xenograft rejection |
| 02/09/1999 | US5868757 For use with an imaging device |
| 02/09/1999 | CA2160137C Bicyclic ansamycins |
| 02/04/1999 | WO1999005299A1 Methods of using cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy |
| 02/04/1999 | WO1999005269A2 Transcriptional silencer protein nrf |
| 02/04/1999 | WO1999005263A1 Anti-invasive and anti-angiogenic urokinase fragments and their use |
| 02/04/1999 | WO1999005175A2 Diagnosis and treatment of diseases using anti-anti-t-cell receptor vbeta anti-bodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein i (esrp1) |
| 02/04/1999 | WO1999005174A1 The ha-1 antigen |
| 02/04/1999 | WO1999005173A1 The ha-1 antigen |
| 02/04/1999 | WO1999005171A1 NOVEL ESTROGEN RECEPTOR β AND ISOFORMS |
| 02/04/1999 | WO1999005170A1 NOVEL ESTROGEN β RECEPTOR AND ISOFORMS |
| 02/04/1999 | WO1999005138A1 Heterocyclic compounds and antitumor agent containing the same as active ingredient |
| 02/04/1999 | WO1999005136A1 Macrocyclic lactones, compositions, and methods of use |
| 02/04/1999 | WO1999005135A1 Polyophenol compounds and drugs containing the same |
| 02/04/1999 | WO1999005134A1 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 02/04/1999 | WO1999005123A1 Novel pyrimidin derivatives |
| 02/04/1999 | WO1999005117A1 Hydantoin derivatives having an inhibitory activity for farnesyl transferase |
| 02/04/1999 | WO1999005103A2 2o(s)-7-ethyl-9-(n-methyl-n-phenyl)amidino-camptothecin, its preparation and its use as antitumor agent |
| 02/04/1999 | WO1999005096A2 Urokinase inhibitors |
| 02/04/1999 | WO1999004821A2 Immobilization of vitamin a acid by cationic polyelectrolytes |
| 02/04/1999 | WO1999004820A2 Cytolysis of target cells by superantigen conjugates inducing t-cell activation |
| 02/04/1999 | WO1999004819A1 Liposomal compositions for the delivery of nucleic acid catalysts |
| 02/04/1999 | WO1999004810A2 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
| 02/04/1999 | WO1999004806A1 Methods and compositions for inhibiting angiogenesis |
| 02/04/1999 | WO1999004792A1 Novel azatyrosine analogues and process of preparation thereof |
| 02/04/1999 | WO1999004776A1 Antitumor agents |
| 02/04/1999 | WO1998051337A3 Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors |
| 02/04/1999 | WO1998050433A3 Human monoclonal antibodies to epidermal growth factor receptor |
| 02/04/1999 | WO1998050424A3 Human serine protease precursor |
| 02/04/1999 | WO1998050419A3 4-aza-steroids as inhibitors of testosterone-5-alpha-reductase |
| 02/04/1999 | WO1998050016A3 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| 02/04/1999 | DE19732903A1 Pellet-Formulierung zur Behandlung des Intestinaltraktes The pellet formulation for the treatment of the intestinal tract |
| 02/04/1999 | CA2732570A1 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
| 02/04/1999 | CA2301166A1 Liposomal compositions for the delivery of nucleic acid catalysts |
| 02/04/1999 | CA2298930A1 Pharmaceuticals for modulating hormone responsiveness |
| 02/04/1999 | CA2298887A1 The ha-1 antigen |
| 02/04/1999 | CA2298065A1 Immobilization of vitamin a acid by cationic polyelectrolytes |
| 02/04/1999 | CA2298053A1 Novel estrogen receptor .beta. and isoforms |
| 02/04/1999 | CA2297907A1 Human estrogen receptor beta |
| 02/04/1999 | CA2296798A1 Directed cytolysis of target cells, agents and compositions causing cytolysis, and compounds that can be used to produce the agents |
| 02/04/1999 | CA2296518A1 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 02/04/1999 | CA2296478A1 Antitumor agents |
| 02/04/1999 | CA2294300A1 Urokinase inhibitors |
| 02/04/1999 | CA2269772A1 Anti-invasive and anti-angiogenic urokinase fragments and their use |
| 02/04/1999 | CA2266891A1 Amidino-camptothecin derivatives |
| 02/04/1999 | CA2239267A1 Novel compounds |
| 02/03/1999 | EP0894863A1 A YAK-1 related serine/threonine protein kinase-HTLAR33 |
| 02/03/1999 | EP0894855A2 Human I kappa B-beta transcription factor |
| 02/03/1999 | EP0894854A2 A novel splicing variant of the epstein-barr virus-induced g-protein coupled receptor |
| 02/03/1999 | EP0894853A1 Transcriptional silencer protein NRF, nucleic acid molecules encoding it and their use |
| 02/03/1999 | EP0894789A1 Substituted indole-2-carboxylic acids as glucosyl transferase inhibitors |
| 02/03/1999 | EP0894139A1 Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
| 02/03/1999 | EP0894135A1 Multivalent and multispecific antigen-binding protein |
| 02/03/1999 | EP0894134A1 Exodus chemokine materials and methods |
| 02/03/1999 | EP0894130A1 Modulators of tnf receptor associated factor (traf), their preparation and use |
| 02/03/1999 | EP0894093A2 Soluble tachykinin antagonists, the preparation and use thereof |
| 02/03/1999 | EP0894092A1 A cyclic hepta-peptide derivative from colonial ascidians, lissoclinum sp. |
| 02/03/1999 | EP0894084A1 Cinnamic acid derivatives and their use as integrin antagonists |